Changes in Blood Cell Production Over the Lifetime Could Impact Leukemia Outcomes Dec. 5, 2024 — The first comprehensive map of the dramatic changes that take place in the blood system over the ...

Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

Celgene's European leader Tuomo Pätsi talks to pharmaphorum about the firm's remarkable growth, which is set to continue thanks to myeloma blockbuster Revlimid and new psoriasis and psoriatic ...

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Disclosures: This research was supported by Bristol Myers Squibb, Celgene, and a University of Chicago Medicine Comprehensive Cancer Center support grant. Some study authors disclosed conflicts of ...

DISCLOSURES: Orlowski previously reported research funding from Asylia Therapeutics, Biotheryx, and Heidelberg Pharma AG and has served on advisory boards for Amgen, Bristol Myers Squibb, Celgene, ...

After hours: March 12 at 7:51:23 PM EDT Loading Chart for BMY ...